Webinar: Understanding and Targeting Immune Evasion Mechanisms in Small Cell Lung Cancer
Join our supplier MCE's upcoming webinar! Learn about the mechanisms of immune evasion and resistance to immune checkpoint blockade in small cell lung cancer (SCLC). Prof. Dr. Lydia Meder from the University of Erlangen-Nuremberg will discuss current research on SCLC metastasis and emerging therapeutic approaches targeting ERBB2 signaling to improve anti-tumor immune responses.
Online
About this webinar:
Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer and is often associated with rapid disease progression, metastasis, and resistance to current treatments. A better understanding of the molecular mechanisms that drive immune evasion and therapy resistance is critical for the development of more effective treatment strategies. In this webinar, Prof. Dr. Lydia Meder from the University of Erlangen-Nuremberg will provide insights into the mechanisms underlying SCLC metastasis, immune escape, and resistance to immune checkpoint blockade. The session will also highlight emerging approaches to enhance anti-tumor immune responses through targeted therapeutic interventions.
Registration & more information
In this webinar, you will learn:
- Targeting molecular mechanisms of SCLC metastasis formation.
- Mechanisms of SCLC resistance to immune checkpoint blockade and immune evasion.
- Targeting ERBB2 signaling induces MHC-I expression and improves the response to immune checkpoint blockade.
About the speaker:
Prof. Dr. Lydia Meder is a researcher at the University of Erlangen-Nuremberg with expertise in lung cancer biology and translational cancer research. Her work focuses on understanding the molecular mechanisms of tumor progression, metastasis, and therapeutic resistance to identify new treatment opportunities for cancer patients.